RSV postfusion F antibody 131-2a sequencing
downstream-application
RSV postfusion F antibody 131-2a sequencing: downstream-application. De novo MS sequencing of the widely used anti-RSV-F antibody 131-2a enabled a recombinant version and a structure explaining its postfusion specificity.
De novo MS sequencing of the widely used anti-RSV-F antibody 131-2a enabled a recombinant version and a structure explaining its postfusion specificity.
| Kind | downstream-application |
| Acquisition | DDA |
| Application area | Antibodyomics |
Data
What the papers describing this method trained it on and reported its results on, as each paper states it. A version is named only where the paper names one.
Deposited
- MS-based sequence of anti-RSV-F monoclonal antibody 131-2a (as deposited)
Paper describing it
- Structural Basis for Postfusion-Specific Binding to the Respiratory Syncytial Virus F Protein by the Canonical Antigenic Site I Antibody 131–2a (2025, ACS Infectious Diseases, peer-reviewed)